Patient in China achieves complete remission from leukemia after CAR T-Cell therapy

Share This Post

Feb 2022: In China, a patient whose life was on the verge of ending was entirely healed of leukaemia thanks to CAR T-cell therapy, which stimulated the immune system. All cancer cells vanished swiftly in the first study of its kind. Immune-mediated therapy, which was pioneered in the United States by ACGT scientists such as Dr. Carl June of the University of Pennsylvania and Dr. Michel Sadelain of Memorial-Sloan Kettering Cancer Center, among others, is rapidly proving more and more successful in human trials with thousands of patients.

After being treated with CAR T-cell therapy, a middle-aged woman was reportedly cured of leukaemia. The cancer cells in her body have vanished. Professor Qian Cheng, director of the Bio-Treatment Center at the hospital in Chongqing, said, “She is the first patient who has been entirely cured of the condition via gene therapy.
Leukemia has been diagnosed in roughly four million people in China.

CAR T treatment is a gene therapy that uses modified T cells to fight cancer cells in leukaemia patients. Most patients are treated with chemotherapy or bone marrow transplants. “CAR T therapy is a far better alternative,” Professor Qian said, “since it can lower expenditures by at least 30% compared to bone marrow transplants and is more likely to lead to a cure.”

According to Professor Qian, six other patients getting gene therapy at the same institution have improved their health. In China, CAR T gene therapy is still in the clinical trial stage, with only ten hospitals across the country having received it. The success has encouraged Qian’s team, which will continue to research doses in order to develop the novel medication.

+ posts

Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. His career is marked by significant contributions to stem cell biology, developmental biology, and innovative research techniques.

Research Highlights

Dr. Mittal's research has focused on several key areas:

1) Cardiovascular Development and Regeneration: He studied coronary vessel development and regeneration using zebrafish models1.

2) Cancer Biology: At Dartmouth College, he developed zebrafish models for studying tumor heterogeneity and clonal evolution in pancreatic cancer.
3) Developmental Biology: His doctoral work at Keio University involved identifying and characterizing medaka fish mutants with cardiovascular defects.

4) Stem Cell Research: He investigated the effects of folic acid on mouse embryonic stem cells and worked on cryopreservation techniques for hematopoietic stem cells.

Publications and Presentations

Dr. Mittal has authored several peer-reviewed publications in reputable journals such as Scientific Reports, Cardiovascular Research, and Disease Models & Mechanisms1. He has also presented his research at numerous international conferences, including the Stanford-Weill Cornell Cardiovascular Research Symposium and the Weinstein Cardiovascular Development Conference.

In summary, Dr. Nishant Mittal is a dedicated and accomplished researcher with a strong track record in cardiovascular and cancer biology, demonstrating expertise in various model systems and a commitment to advancing scientific knowledge through innovative research approaches.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment
CAR T-Cell therapy

Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment

CAR T cell therapy has transformed cancer treatment, especially in hematological malignancies. Treatment of solid tumors remains challenging due to their immunosuppressive tumor microenvironment. Combination with chemotherapy, immune checkpoint inhibitors, oncolytic viruses, and improved genetic engineering holds promise. Multimodal approaches enhance immune cell infiltration and persistence, raising efficacy. Evolving personalized methods will be instrumental in overcoming solid tumor resistance and improving patient outcomes.

How to prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies
CAR T-Cell therapy

How to prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies?

CAR T-cell therapy revolutionized cancer therapy, offering incredible success in the management of B-cell malignancies, but it is associated with severe infection risks secondary to immunosuppression. Preventive measures are pre-infusion screening, vaccination, and antimicrobial prophylaxis. Post-infusion, close surveillance for infection and cytokine release syndrome management are key. Long-term care includes the treatment of hypogammaglobulinemia, revaccination, and patient education. The approach ensures improved outcomes and reduces infection-related complications in patients receiving CD19-targeted CAR T-cell therapy.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟